![FDA Watch: Key Lab Test Clearances of 2023](https://www.g2intelligence.com/wp-content/uploads/2024/01/Jan24.LIA_.FDAWatch-iStock-1100x800-1-1080x675.jpg)
FDA Watch: Key Lab Test Clearances of 2023
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Here are what G2 Intelligence considers the three most significant deals announced in the period from late August to early September.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.